EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma

Chika Nitani, Junichi Hara, Hiroshi Kawamoto, Tomoaki Taguchi, Yuki Yuza, Shuhei Karakawa, Kimikazu Matsumoto, Toshimi Kimura, Kenichi Yoshimura, Kiyoshi Yoshimura, Akinobu Hamada

International Journal of Clinical Oncology · 2026

DOI: 10.1007/s10147-026-03142-8 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Clinical Oncology, 2026. Verfasst von Chika Nitani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, Osaka City General Hospital, 2-13-22 Miyakojima-Hondori, Miyakojima-Ku, Osaka, 534-0021, Japan. c-ta…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Gangliosides, Neuroblastoma. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Granulocyte–macrophage colony-stimulating factor (GM-CSF), aldesleukin and isotretinoin are unavailable in Japan, necessitating alternative cytokines for dinutuximab immunotherapy. We compared the efficacy of a regimen containing granulocyte colony-stimulating factor (G-CSF)/teceleukin (regimen A) to that with GM-CSF/aldesleukin/isotretinoin (regimen B) in children with newly diagnosed high-risk neuroblastoma.

Methods

After completing initial therapy including high-dose chemotherapy followed by autologous stem cell transplantation and radiotherapy, children with non-progressive disease were randomized to regimen A or B. Regimen B was identical to the immunotherapy regimen tested in ANBL0032 (six cycles of isotretinoin and five concomitant cycles of dinutuximab alternating with GM-CSF and aldesleukin). Regimen A consisted of six cycles of dinutuximab alternating with G-CSF and teceleukin. Event-free survival (EFS) and overall survival (OS) were compared between two regimens.

Results

In total, 35 patients (16 receiving regimen A and 19 receiving regimen B) were enrolled. The 2-year EFS was 80.8% for patients receiving regimen A and 62.3% for those receiving regimen B, and their OS rates were 93.8% and 100.0%, respectively. The hazard ratio of regimen A compared to regimen B for EFS was 0.494 (upper limit of one-sided 70% confidence interval: 0.710), suggesting comparable efficacy of the two regimens. Frequently recorded grade 3/4 adverse events were fever, infection, and hematologic toxicity with no obvious difference in incidence between the regimens.

Conclusions

Our results suggest that the efficacy of the alternative regimen containing G-CSF is comparable to that of the ANBL0032 regimen, providing a rationale for further evaluation in a phase III trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsGangliosidesNeuroblastomaChildChild, PreschoolFemaleHumansInfantMaleFilgrastimGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorImmunotherapyIsotretinoinRecombinant Proteins

Stichwörter der Autor:innen

G-CSFGD2 antibodyImmunotherapyNeuroblastoma

Substanzen

Antibodies, MonoclonaldinutuximabFilgrastimganglioside, GD2GangliosidesGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorIsotretinoinRecombinant Proteinssargramostim

Autor:innen und Institutionen

  • Department of Pediatric Hematology and Oncology, Osaka City General Hospital, 2-13-22 Miyakojima-Hondori, Miyakojima-Ku, Osaka, 534-0021, Japan. c-tanaka@med.osakacity-hp.or.jp.
  • Department of Pediatric Hematology and Oncology, Osaka City General Hospital, 2-13-22 Miyakojima-Hondori, Miyakojima-Ku, Osaka, 534-0021, Japan.
  • Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Pediatric Surgery, Kyushu University Hospital, Fukuoka, Japan.
  • Department of Hematology and Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
  • Department of Pediatrics, Hiroshima University Hospital, Hiroshima, Japan.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Nitani, C., Hara, J., Kawamoto, H., Taguchi, T., Yuza, Y., Karakawa, S., Matsumoto, K., Kimura, T., Yoshimura, K., Yoshimura, K., & Hamada, A. (2026). Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03142-8

Vancouver

Nitani C, Hara J, Kawamoto H, Taguchi T, Yuza Y, Karakawa S, et al. Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma. International Journal of Clinical Oncology. 2026. doi:10.1007/s10147-026-03142-8

BibTeX
@article{Nitani2026,
  author = {Nitani, Chika and Hara, Junichi and Kawamoto, Hiroshi and Taguchi, Tomoaki and Yuza, Yuki and Karakawa, Shuhei and Matsumoto, Kimikazu and Kimura, Toshimi and Yoshimura, Kenichi and Yoshimura, Kiyoshi and Hamada, Akinobu},
  title = {Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1007/s10147-026-03142-8}
}
Kostenlos starten →